Company: Johnson & Johnson
Ticker: JNJ
Form: 10-K
Filed: 2026-02-11
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Johnson & Johnson's revenue in fiscal year 2025?
Question Type: value_lookup

Concept: RevenueFromContractWithCustomerExcludingAssessedTax
Answer (Numeric): 94193.0
Answer (Display): $94,193 million
Unit: USD millions

Evidence:
[{"chunk_id": "154", "equivalent_chunk_ids": ["154"], "section": "Notes to consolidated financial statements", "supports": ["main"], "text": "4,669\n22,915\n(Income) Expense not allocated to segments\n6,202\n5,972\n7,853\nWorldwide total\n32,581\n16,687\n15,062\nIdentifiable Assets\n(Dollars in Millions)\nInnovative Medicine\n78,057\n57,070\nMedTech\n86,482\n84,322\nTotal\n164,539\n141,392\nGeneral corporate\n34,671\n38,712\nWorldwide total\n199,210\n180,104\nAdditions to Property,\nPlant & Equipment\nDepreciation and\nAmortization\n(Dollars in Millions)\nInnovative Medicine\n2,076\n1,710\n1,653\n3,772\n3,760\n3,847\nMedTech\n2,501\n2,443\n2,372\n3,490\n3,237\n2,943\nSegments total\n4,577\n4,153\n4,025\n7,262\n6,997\n6,790\nDiscontinued operations\nGeneral corporate\nWorldwide total\n4,832\n4,424\n4,543\n7,503\n7,339\n7,486\n2025 Annual Report\nSales to Customers\nLong-Lived Assets\n(Dollars in Millions)\nUnited States\n53,752\n50,302\n46,444\n89,392\n70,670\nEurope\n21,535\n20,212\n20,410\n27,987\n27,267\nWestern Hemisphere excluding U.S.\n4,875\n4,714\n4,549\n2,204\n1,728\nAsia-Pacific, Africa\n14,031\n13,593\n13,756\n1,544\n1,454\nSegments total\n94,193\n88,821\n85,159\n121,127\n101,119\nGeneral corporate\n1,217\nOther non long-lived assets\n76,866\n77,768\nWorldwide total\n94,193\n88,821\n85,159\n199,210\n180,104\nSee Note 1 for a description of the segments in which the Company operates.\nExport sales are not significant. In fiscal year 2025, the Company utilized three wholesalers distributing products for both segments that represented approximately\n21.8\n15.5\n% and\n11.1\n% of the total gross revenues. In fiscal year 2024, the Company had three wholesalers distributing products for both segments that represented approximately\n20.5\n15.6\n% and\n12.3\n% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately\n18.2\n15.1\n%, and\n14.2\n% of the total gross revenues.\nOther segment expenses\nfor each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.\nAmounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal year 2025 includes the reversal of approximately $\nbillion, a significant portion of the previously accrued talc reserve. The fiscal years 2024 and 2023 include charges for talc matters of approximately $\nbillion and $\nbillion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $\nbillion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $\nbillion.\nInnovative Medicine segment income before tax includes:"}]

Derivation: